Demand for Fertility Preservation Increasing for Women

Share this content:
Demand for Fertility Preservation Increasing for Women
Demand for Fertility Preservation Increasing for Women

THURSDAY, Oct. 26, 2017 (HealthDay News) -- The demand for fertility preservation is increasing, and methods to address it include oocyte cryopreservation and ovarian-tissue cryopreservation, according to a review article published online Oct. 25 in the New England Journal of Medicine.

Jacques Donnez, M.D., Ph.D., and Marie-Madeleine Dolmans, M.D., Ph.D., from the Université Catholique de Louvain in Belgium, discussed methods for fertility preservation in women.

Indications for fertility preservation include malignant disease, particularly hematologic cancers and breast cancer; benign conditions including autoimmune and hematologic conditions as well as endometriosis and ovarian torsion; and age-related fertility decline. The researchers note that oocyte cryopreservation by vitrification provides the highest yield and is suitable for women with benign diseases, those seeking fertility preservation for personal reasons, and women with cancer if treatment can be delayed. Embryo cryopreservation requires a male partner or use of a donor sperm; cryopreservation of mature oocytes can circumvent some related ethical and legal concerns. For adolescents and women in whom cancer treatment cannot be postponed, ovarian-tissue cryopreservation is specifically indicated; however, this technique is still considered experimental.

"Improving freezing techniques, ensuring safe ovarian-tissue transportation (to provide and extend access to fertility preservation in large countries and low-resource areas), and minimizing the risks of fertility-preservation strategies in patients with cancer constitute formidable challenges for the coming decade," the authors write.

One author disclosed ties to Gedeon Richter.

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

Lab  Companion Tests Perform Similarly for Oncology Analytes

Lab + Companion Tests Perform Similarly for Oncology ...

Findings based on comparison of tests to diagnose oncology-related genetic variants

Ulixertinib Is Active in Patients With Advanced Solid Tumors

Ulixertinib Is Active in Patients With Advanced Solid ...

Responses occurred in patients with NRAS-, BRAF V600-, non-V600 BRAF-mutant solid tumors

Doctors Must Report on at Least 1 Patient, 1 Measure for MACRA

Doctors Must Report on at Least 1 Patient, ...

To avoid Medicare payment penalty in 2019, clinicians must report by Dec. 31, submit by Feb. 28

is free, fast, and customized just for you!

Already a member?

Sign In Now »